CPhI grades Japan in the second position for Pharma

Industry supervisors envisage Japan to be the second fastest growing mature marketplace for solid dose drugs in 2019 followed by the United States. The findings represent a considerable year-on-year improvement in outlook for pharma in Japan with expected growth of solid dose formulations improving by more than 10% with generic drug classes highlighted Significantly, it ranks ahead of all EU nations and Korea. The report concludes that Japan is a ripened country for growth across a number of product classes, but the enduring winners of regulatory changes and innovative R&D remain hard to pick.

Reference Link: https://biospectrumasia.com/news/50/12865/japan-second-fastest-pharma-growth-in-2019-cphi-report.html